Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content.
Anti-GPIbα
multirefractory ITP
oseltamivir
platelet activation
sialic acid
Journal
Platelets
ISSN: 1369-1635
Titre abrégé: Platelets
Pays: England
ID NLM: 9208117
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
9
10
2018
medline:
18
12
2019
entrez:
9
10
2018
Statut:
ppublish
Résumé
Patients with multirefractory immune thrombocytopenia (ITP) have limited treatment options. Recent data suggest that specific anti-platelet antibodies may cause destruction of platelets by favoring platelet loss of sialic acid. In this multicenter study 35 patients with ITP, including 16 with multirefractory disease, were analyzed for antiplatelet-antibodies, thrombopoietin (TPO) levels, and platelet desialylation. In selected cases, responses to a novel treatment strategy using oseltamivir were tested. We found that antibodies against GPIbα were overrepresented in multirefractory patients compared to responders (
Identifiants
pubmed: 30296193
doi: 10.1080/09537104.2018.1513476
doi:
Substances chimiques
N-Acetylneuraminic Acid
GZP2782OP0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM